SCHEMBL5406592

SCHEMBL5406592

CCN(CC)CCNC(=O)Cc1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.63
PDGFRB P09619 6/20 0.63
FGFR1 P11362 5/20 0.63
EGFR P00533 4/20 0.63
PRKAA1 Q13131 13/20 0.58
PRKAA2 P54646 12/20 0.58
FLT3 P36888 4/20 0.58
PLK4 O00444 2/20 0.58
DCLK1 O15075 2/20 0.58
PDPK1 O15530 2/20 0.58
DAPK3 O43293 2/20 0.58
ROCK2 O75116 2/20 0.58
RPS6KA5 O75582 2/20 0.58
RPS6KA4 O75676 2/20 0.58
MAP4K4 O95819 2/20 0.58
CHEK2 O96017 2/20 0.58
NTRK1 P04629 2/20 0.58
INSR P06213 2/20 0.58
LCK P06239 2/20 0.58
FYN P06241 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5396558 0.91 KDR (0.57) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL5417668 0.91 SRC (0.59) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL6514631 0.87 KDR (0.56) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL5407073 0.84 KDR (0.62) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL5410105 0.84 MET (0.61) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL5414487 0.83 AURKB (0.63) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL5396486 0.82 KDR (0.61) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL15202708 0.80 KDR (0.79) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL15202709 0.80 KDR (0.77) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL13755242 0.78 KDR (0.75) KDRPDGFRBFGFR1EGFRPRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 KDR 1657/4885PDGFRB 913/4885FGFR1 1118/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM KDR 1541/4885PDGFRB 1414/4885FGFR1 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.